Massive Update Reveals Multiple New Areas and Exciting Challenges for ‘MIR4’
Wemade performed a substantial update today to its widely acclaimed MMORPG, ‘MIR4’. Along with the introduction of new areas, Rockcut Tomb and Bladehaven, further changes include: an increase to the maximum character growth from Level 130 to Level 150, the addition of a new Boss Raid Clan Expedition as well as an expansion to Constitution and Inner Force.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220502005953/en/
Wemade performed a substantial update to its widely acclaimed MMORPG, MIR4. Along with the introduction of new areas, Rockcut Tomb and Bladehaven, further changes include: an increase to the maximum character growth from Level 130 to Level 150, the addition of a new Boss Raid Clan Expedition as well as an expansion to Constitution and Inner Force. (Graphic: Business Wire)
Rockcut Tomb and Bladehaven are ancient ruined hunting grounds located in the eastern part of the Phantasia Area. The addition of these new areas allows players to enjoy more diverse contents through enriched quests, stories, and missions. Additionally, a new area will be opened within Sabuk, including Sabuk Castle where a new dynamic story will unfold!
Along with the increase to the maximum character level from Level 130 to Level 150, the maximum Promotion Level for all Conquest buildings has increased to 19. By upgrading the Conquest Tower to 19, it is possible to reach the maximum level of 150.
In other changes, Constitution and Inner Force has been expanded to Tier 15 and 14 respectively, and there have been some new additions, including the new Mysteries ‘Wedding Vow’, the new boss fight ‘Deranged Hellbound Revenant’ and Clan Expedition ‘Azure Flame Emperor’, both of which can be challenged by users at Level 90 or higher. This extensive update allows players to unlock the full potential of their characters.
‘MIR4’ was released in August 2021 and since then, it has broken many records with over 200 servers and more than 1.4 million global concurrent users. The game’s economy continues to grow through the introduction of unique systems such as MIRAGE, an NFT character staking game, as well as HYDRA Payment which utilizes HYDRA, a DeFi utility token for ‘MIR4’, to purchase goods in the game. The present update offers players a plethora of content to enjoy, while upcoming additions will introduce a new transcendent boss named ‘Violet Demon God Turkan’ which will require large numbers of players to defeat.
‘MIR4’ continues to add new fun content and strives to evolve and grow the game’s economy. Visit MIR4 Global to find more information on these exciting updates and new challenges.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
Wemade Co., Ltd. (112040: KOSDAQ)
Yeonghyun Lee, PR Manager
About Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
CARVYKTI ® (ciltacabtagene autoleucel) Granted Conditional Approval by the European Commission for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma26.5.2022 09:10:00 CEST | Press release
Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, today announced that the European Commission (EC) has granted conditional marketing authorization of CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) for the treatment of adults with relapsed and refractory multiple myeloma (RRMM) who have received at least three prior therapies, including a proteasome inhibitor (PI), an immunomodulatory agent (IMiD) and an anti-CD38 antibody, and have demonstrated disease progression on the last therapy. Legend Biotech entered into an exclusive worldwide license and collaboration agreement with Janssen Biotech, Inc. (Janssen) to develop and commercialize cilta-cel in December 2017. CARVYKTI® is a chimeric antigen receptor T-cell (CAR-T) therapy featuring two B-cell maturation antigen (BCMA)-targeting single domain antibodies.1 CAR-T therapy is specifically developed
European Commission Grants Conditional Approval of CARVYKTI ® (Ciltacabtagene Autoleucel), Janssen’s First Cell Therapy, for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma26.5.2022 09:00:00 CEST | Press release
The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the European Commission (EC) granted conditional marketing authorisation of CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) for the treatment of adults with relapsed and refractory multiple myeloma (RRMM) who have received at least three prior therapies, including an immunomodulatory agent (IMiD), a proteasome inhibitor (PI) and an anti-CD38 antibody, and have demonstrated disease progression on the last therapy. In December 2017, Janssen Biotech, Inc. (Janssen) entered into an exclusive worldwide license and collaboration agreement with Legend Biotech USA, Inc. to develop and commercialise cilta-cel.2 “Patients who have relapsed, or for whom treatment regimens have stopped working after experiencing the three major drug classes, typically face poor survival. Despite recent innovation, new therapeutic approaches are still needed,” said Maria-Victoria Mateos, M.D., Ph.D., Consultant Physician in Haematology,
SCREEN Increases Efforts to Reduce the Environmental Impact of the Semiconductor Industry26.5.2022 06:30:00 CEST | Press release
SCREEN Semiconductor Solutions Co., Ltd. (SCREEN SPE), a subsidiary of SCREEN Holdings Co., Ltd., has announced it will increase its efforts to reduce the company’s environmental overall impact. The SCREEN Group is committed to both achieving a sustainable global society and to improving its sustainable value (social value) and has formulated a medium-term management plan titled Sustainable Value 2023 targeting these goals. The plan identifies specific issues in each of the environmental, social, and governance (ESG) fields. Concerning the environment, SCREEN is working to provide products and services that actively contribute to the reduction of ecological burden. Its efforts include improving the environmental performance of its products, reducing the effects of its business activities on climate change, promoting effective utilization of water resources, increasing recycling of products and parts, and helping to preserve biodiversity. Concretely, SCREEN SPE seeks to reduce the impac
Lenovo Group: Full Year Financial Results 2021/2226.5.2022 06:19:00 CEST | Press release
Lenovo Group (HKSE: 992) (ADR: LNVGY) today announced record fiscal year results for the Group, with historic highs for both profit and revenue. Annual net income reached the US$2 billion mark, up 72% year on year, with revenue growing by US$10 billion for the second year running to over US$71 billion. All main business groups were profitable for the full fiscal year - with strong growth momentum in mobile, infrastructure, and solutions and services businesses. Lenovo successfully overcame macro-environmental challenges and demonstrated both agility and resilience as it navigated industry-wide supply shortages, pandemic disruption, geopolitical uncertainties, and higher inflation to deliver a record year. The digital and intelligent transformation trend continues to accelerate, presenting the Group with strong growth opportunities. More than 50% of companies now have digitalization as part of their corporate strategy, up from just over one third two years ago. The hybrid work model is
Exscientia Business Update for First Quarter 202225.5.2022 22:01:00 CEST | Press release
Exscientia plc (Nasdaq: EXAI) This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220525005906/en/ Recent advancements in the Company’s pipeline, collaborations, and operations, as well as financial results for the first quarter 2022, are summarised below. In addition, Exscientia will host a conference call Thursday, May 26 at 1:30 p.m. BST / 8:30 a.m. ET to provide an overview of the Company's precision medicine platform. "We started 2022 by commencing a groundbreaking collaboration with Sanofi to develop a pipeline of AI-designed medicines utilising the breadth of our end-to-end platform of AI-driven capabilities from target prioritisation, to drug engineering and patient selection. At this year's American Association of Cancer Research (AACR) Annual Meeting, we highlighted our advancements in this area, including how AI-enabled drug design can help create drug candidates for challenging targets in oncology. In addition, we sho